ArticleEuropean journal of pediatrics2026
Is methylphenidate truly cardiac-safe? Insight from biventricular speckle tracking echocardiography in pediatric patients with attention deficit hyperactivity disorder.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental condition identified by inattention, hyperactivity, and impulsivity. ADHD pharmacotherapy, particularly methylphenidate (MPH), has raised concerns about its cardiovascular safety. We aimed to assess the impact of methylphenidate on cardiac function in pediatric patients with ADHD using two-dimensional speckle tracking echocardiography (2D-STE). This study was performed on 40 children with newly diagnosed ADHD as the patient group and 40 age- and sex-matched healthy controls. Electrocardiographic screening and echocardiographic evaluations were conducted at baseline and after 6 months of MPH treatment. Heart rate (HR) and systolic and diastolic blood pressure (SBP, DBP) were also recorded. HR, SBP and DBP, were significantly elevated after treatment compared with their pre-treatment values. Diastolic functions of the left and right ventricles measured by tissue Doppler echocardiography (TDE) decreased significantly after treatment compared to their pretreatment values. Moreover, right and left ventricular systolic function measured by 2D-STE was significantly reduced after treatment compared to their pretreatment values. However, conventional echocardiography failed to detect any changes. None of our patients experienced any arrhythmias throughout the study duration.
conclusionSubclinical cardiac systolic and diastolic alterations were detected in pediatric ADHD patients treated with methylphenidate. The safety of the drug for the heart is warranted; therefore, careful patient selection, baseline cardiovascular assessment, and follow-up of these patients are strongly recommended. WHAT IS KNOWN: • Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental condition characterized by inattention, hyperactivity, and impulsivity. • ADHD pharmacotherapy, particularly methylphenidate (MPH), has raised concerns about its cardiovascular safety. No sufficient data about its cardiac safety in pediatrics. WHAT IS NEW: • We investigated, for the first time, the effect of methylphenidate on cardiac function in pediatric patients with ADHD using two-dimensional speckle tracking echocardiography. • We found subclinical cardiac systolic and diastolic alterations in pediatric ADHD patients treated with methylphenidate. The safety of the drug on the heart is warranted; therefore, careful patient selection, baseline cardiovascular assessment, and follow-up of these patients are strongly recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.